Analysis | Metabolite Name | Measured Value | Units | AGE | DIET | SAMPLE_TYPE |
---|---|---|---|---|---|---|
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 9.77761728 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 99.14147004 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 125.2372598 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 219.0766303 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 673.1493586 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 827.7553823 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 958.8862948 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 976.5388098 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1074.224236 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1275.724394 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1352.698163 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1385.102849 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1485.980061 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1512.920249 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1526.899091 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1532.374442 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1538.719009 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1583.501803 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1594.323071 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1783.486909 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1800.561779 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1805.647717 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1892.158723 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 1930.479408 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2186.739797 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2210.111364 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2346.165679 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2479.33966 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2544.903765 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2557.656652 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2723.797337 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2755.882375 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2765.679096 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2781.560764 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2799.846891 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2827.995521 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2867.10291 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2872.592844 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 2917.981946 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3064.693304 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3180.150256 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3189.451851 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3226.298199 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3242.46494 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3404.467019 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3452.781233 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3541.05805 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3645.873764 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3680.231901 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3839.118493 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3885.18153 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3909.369187 | Peak area normalized | 24 week | HF DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3964.890411 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 3975.595512 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4036.904703 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4062.014421 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4091.096218 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4315.705727 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4418.585766 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4422.082329 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4465.471358 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4548.986085 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4577.536416 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4580.309722 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4729.132216 | Peak area normalized | 16 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4835.559458 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4871.145749 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 4925.916069 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5051.475949 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5114.8293 | Peak area normalized | 24 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5179.183832 | Peak area normalized | 16 week | Control | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5278.506234 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5442.736668 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5506.719761 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5507.634381 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5527.068593 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5568.28533 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5777.701571 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5778.125345 | Peak area normalized | 24 week | HF STZ DR | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5872.655962 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5877.592055 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 5939.069389 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6014.408076 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6015.389423 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6031.491936 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6242.448938 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6320.661424 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6401.412495 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6505.697815 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6527.332085 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6536.731074 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6620.953264 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6717.630904 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6779.700769 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6796.533265 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6872.897693 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6896.149187 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6931.302771 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 6951.734031 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7065.595148 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7285.163812 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7311.653295 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7399.909559 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7597.68003 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7906.034351 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 7922.910674 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8004.570063 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8198.416416 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8338.435178 | Peak area normalized | 16 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8422.059119 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8545.193706 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8617.594115 | Peak area normalized | 24 week | HF STZ | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8638.846613 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8800.61443 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 8813.199539 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 9054.575804 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 9281.330071 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 9657.651159 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 9669.563676 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 9981.10899 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 10017.64934 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 10078.52779 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 10202.22992 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 10629.89246 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 10711.57827 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 10894.6633 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 11138.30751 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 11190.33206 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 11641.08959 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 11828.35962 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 12086.09624 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 12171.53457 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 12217.73709 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 12961.37447 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 13053.21183 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 13095.9416 | Peak area normalized | 24 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 13422.41715 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 13615.65923 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 13762.50623 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 14042.54592 | Peak area normalized | 24 week | HF | plasma |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 14488.73681 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 15206.03726 | Peak area normalized | 24 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 15562.73569 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 16437.20226 | Peak area normalized | 16 week | control | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 16551.27275 | Peak area normalized | 24 week | HF STZ DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 16894.73077 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 17557.14896 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 18034.33369 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 18087.28318 | Peak area normalized | 16 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 18555.50131 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 19221.94616 | Peak area normalized | 24 week | HF | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 19332.12704 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 20849.00819 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 24134.99381 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 25493.16849 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 27195.3885 | Peak area normalized | 24 week | HF DR | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 29101.8545 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 30451.36248 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 32560.18352 | Peak area normalized | 24 week | HF STZ DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 35775.62455 | Peak area normalized | 24 week | HF STZ DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 37671.53315 | Peak area normalized | 16 week | HF STZ | Sciatic nerve |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 41088.46477 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 41495.42337 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 42414.32487 | Peak area normalized | 24 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 43360.09772 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 44452.79128 | Peak area normalized | 24 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 46377.94651 | Peak area normalized | 24 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 47251.01284 | Peak area normalized | 24 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 48691.91823 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 50223.51846 | Peak area normalized | 24 week | HF DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 50442.23165 | Peak area normalized | 16 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 50785.44418 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 51062.33619 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 51683.43119 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 53568.39954 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 56654.65739 | Peak area normalized | 24 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 57329.12142 | Peak area normalized | 24 week | HF DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 59620.62224 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 61482.16666 | Peak area normalized | 24 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 61939.52142 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 62198.07574 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 64661.86586 | Peak area normalized | 16 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 67787.11454 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 68359.15172 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 68962.16377 | Peak area normalized | 16 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 70294.71516 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 70379.04499 | Peak area normalized | 24 week | HF DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 72702.45174 | Peak area normalized | 24 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 72821.93751 | Peak area normalized | 16 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 73033.36437 | Peak area normalized | 24 week | HF DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 73922.67593 | Peak area normalized | 24 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 76112.95577 | Peak area normalized | 24 week | HF STZ DR | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 77483.49543 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 79220.18301 | Peak area normalized | 24 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 80224.69366 | Peak area normalized | 24 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 80641.60468 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 82282.85143 | Peak area normalized | 16 week | Control | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 83141.06286 | Peak area normalized | 24 week | HF STZ | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 83461.41306 | Peak area normalized | 16 week | HF | Dorsal root ganglia |
C18 NEGATIVE ION MODE | N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45 | 86796.97261 | Peak area normalized | 24 week | HF STZ DR | Dorsal root ganglia |
Return to search page